{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:40:13Z","timestamp":1718066413838},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anaesthesist"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00101-015-0072-0","type":"journal-article","created":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T08:49:23Z","timestamp":1441702163000},"page":"643-658","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Strategien bei Versagen einer antimykotischen Therapie auf Intensivstation","Strategies for antifungal treatment failure in intensive care units"],"prefix":"10.1007","volume":"64","author":[{"given":"C.","family":"Arens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Heininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"St\u00f6rzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hoppe-Tichy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Grabein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Weigand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lichtenstern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,8]]},"reference":[{"key":"72_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408410903241444","volume":"36","author":"MA Pfaller","year":"2010","unstructured":"Pfaller MA, Diekema DJ (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36:1\u201353","journal-title":"Crit Rev Microbiol"},{"key":"72_CR2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","volume":"348","author":"GS Martin","year":"2003","unstructured":"Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546\u20131554","journal-title":"N Engl J Med"},{"key":"72_CR3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"H Wisplinghoff","year":"2004","unstructured":"Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309\u2013317","journal-title":"Clin Infect Dis"},{"key":"72_CR4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","volume":"34","author":"J-L Vincent","year":"2006","unstructured":"Vincent J-L, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall J-R, Payen D (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:344\u2013353","journal-title":"Crit Care Med"},{"key":"72_CR5","doi-asserted-by":"crossref","unstructured":"Meyer E, Geffers C, Gastmeier P, Schwab F (2013) No increase in primary nosocomial candidemia in 682 German intensive care units during 2006 to 2011. Euro Surveill 18(24):pii=20505","DOI":"10.2807\/ese.18.24.20505-en"},{"key":"72_CR6","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","volume":"366","author":"BJ Kullberg","year":"2005","unstructured":"Kullberg BJ, Sobel JD, Ruhnke M et al (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366:1435\u20131442","journal-title":"Lancet"},{"key":"72_CR7","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","volume":"369","author":"E-R Kuse","year":"2007","unstructured":"Kuse E-R, Chetchotisakd P, da Cunha CA et al (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519\u20131527","journal-title":"Lancet"},{"key":"72_CR8","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","volume":"347","author":"J Mora-Duarte","year":"2002","unstructured":"Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020\u20132029","journal-title":"N Engl J Med"},{"key":"72_CR9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","volume":"45","author":"PG Pappas","year":"2007","unstructured":"Pappas PG, Rotstein CMF, Betts RF et al (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45:883\u2013893","journal-title":"Clin Infect Dis"},{"key":"72_CR10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF01726360","volume":"16","author":"P Phillips","year":"1997","unstructured":"Phillips P, Shafran S, Garber G et al (1997) Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 16:337\u2013345","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"72_CR11","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","volume":"356","author":"AC Reboli","year":"2007","unstructured":"Reboli AC, Rotstein C, Pappas PG et al (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356:2472\u20132482","journal-title":"N Engl J Med"},{"key":"72_CR12","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","volume":"331","author":"JH Rex","year":"1994","unstructured":"Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331:1325\u20131330","journal-title":"N Engl J Med"},{"key":"72_CR13","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","volume":"36","author":"JH Rex","year":"2003","unstructured":"Rex JH, Pappas PG, Karchmer AW et al (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36:1221\u20131228","journal-title":"Clin Infect Dis"},{"key":"72_CR14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M et al (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44:1289\u20131297","journal-title":"Clin Infect Dis"},{"key":"72_CR15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408\u2013415","journal-title":"N Engl J Med"},{"key":"72_CR16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","volume":"35","author":"R Bowden","year":"2002","unstructured":"Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, van Burik J-A, Laverdiere M, Safrin S, Wingard JR (2002) A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 35:359\u2013366","journal-title":"Clin Infect Dis"},{"key":"72_CR17","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","volume":"27","author":"M Ellis","year":"1998","unstructured":"Ellis M, Spence D, de Pauw B et al (1998) An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 27:1406\u20131412","journal-title":"Clin Infect Dis"},{"key":"72_CR18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.11510","volume":"98","author":"M Nucci","year":"2003","unstructured":"Nucci M, Anaissie EJ, Queiroz-Telles F et al (2003) Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 98:315\u2013319","journal-title":"Cancer"},{"key":"72_CR19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","volume":"346","author":"TJ Walsh","year":"2002","unstructured":"Walsh TJ, Pappas P, Winston DJ et al (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225\u2013234","journal-title":"N Engl J Med"},{"issue":"7","key":"72_CR20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Bassetti M, Calandra T et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19\u201337","journal-title":"Clin Microbiol Infect"},{"key":"72_CR21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1439-0507.2011.02040.x","volume":"54","author":"M Ruhnke","year":"2011","unstructured":"Ruhnke M, Rickerts V, Cornely OA et al (2011) Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 54:279\u2013310","journal-title":"Mycoses"},{"key":"72_CR22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","volume":"48","author":"PG Pappas","year":"2009","unstructured":"Pappas PG, Kauffman CA, Andes D et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503\u2013535","journal-title":"Clin Infect Dis"},{"key":"72_CR23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00134-014-3404-7","volume":"40","author":"D Maubon","year":"2014","unstructured":"Maubon D, Garnaud C, Calandra T, Sanglard D, Cornet M (2014) Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive Care Med 40:1241\u20131255","journal-title":"Intensive Care Med"},{"issue":"6","key":"72_CR24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12539","volume":"20","author":"J Guinea","year":"2014","unstructured":"Guinea J (2014) Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 20(Suppl 6):5\u201310","journal-title":"Clin Microbiol Infect"},{"key":"72_CR25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijantimicag.2011.02.016","volume":"38","author":"MA Pfaller","year":"2011","unstructured":"Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M (2011) Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008\u20132009). Int J Antimicrob Agents 38:65\u201369","journal-title":"Int J Antimicrob Agents"},{"key":"72_CR26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s15010-013-0432-0","volume":"41","author":"MT Montagna","year":"2013","unstructured":"Montagna MT, Caggiano G, Lovero G et al (2013) Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection 41:645\u2013653","journal-title":"Infection"},{"key":"72_CR27","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1128\/JCM.01998-13","volume":"51","author":"M Bassetti","year":"2013","unstructured":"Bassetti M, Merelli M, Righi E et al (2013) Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol 51:4167\u20134172","journal-title":"J Clin Microbiol"},{"key":"72_CR28","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","volume":"47","author":"BH Segal","year":"2008","unstructured":"Segal BH, Herbrecht R, Stevens DA et al (2008) Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 47:674\u2013683","journal-title":"Clin Infect Dis"},{"key":"72_CR29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00277-013-1867-1","volume":"93","author":"S Mousset","year":"2014","unstructured":"Mousset S, Buchheidt D, Heinz W et al (2014) Treatment of invasive fungal infections in cancer patients \u2013 updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 93:13\u201332","journal-title":"Ann Hematol"},{"key":"72_CR30","first-page":"360","volume":"22","author":"M Ruhnke","year":"2004","unstructured":"Ruhnke M, Rosseau S, Graf B (2004) Invasive Pilzinfektionen auf Intensivstation. Arzneimitteltherapie 22:360\u2013370","journal-title":"Arzneimitteltherapie"},{"key":"72_CR31","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1128\/JCM.00179-11","volume":"49","author":"MC Arendrup","year":"2011","unstructured":"Arendrup MC, Sulim S, Holm A, Nielsen L, Nielsen SD, Knudsen JD, Drenck NE, Christensen JJ, Johansen HK (2011) Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol 49:3300\u20133308","journal-title":"J Clin Microbiol"},{"key":"72_CR32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1086\/430710","volume":"41","author":"G Chamilos","year":"2005","unstructured":"Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP (2005) Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41:60\u201366","journal-title":"Clin Infect Dis"},{"key":"72_CR33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1148\/radiol.2301020649","volume":"230","author":"PS Pinto","year":"2004","unstructured":"Pinto PS (2004) The CT halo sign. Radiology 230:109\u2013110","journal-title":"Radiology"},{"key":"72_CR34","doi-asserted-by":"crossref","first-page":"W266","DOI":"10.2214\/AJR.10.6208","volume":"197","author":"JP Kanne","year":"2011","unstructured":"Kanne JP, Yandow DR, Mohammed T-LH, Meyer CA (2011) CT findings of pulmonary nocardiosis. AJR Am J Roentgenol 197:W266\u2013W272","journal-title":"AJR Am J Roentgenol"},{"key":"72_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.39.1.1","volume":"39","author":"JH Rex","year":"1995","unstructured":"Rex JH, Rinaldi MG, Pfaller MA (1995) Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 39:1\u20138","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/dkg312","volume":"52","author":"G Kahlmeter","year":"2003","unstructured":"Kahlmeter G, Brown DFJ, Goldstein FW, MacGowan AP, Mouton JW, Osterlund A, Rodloff A, Steinbakk M, Urbaskova P, Vatopoulos A (2003) European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 52:145\u2013148","journal-title":"J Antimicrob Chemother"},{"key":"72_CR37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drup.2014.01.001","volume":"16","author":"MC Arendrup","year":"2013","unstructured":"Arendrup MC, Cuenca-Estrella M, Lass-Fl\u00f6rl C, Hope WW (2013) Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat 16:81\u201395","journal-title":"Drug Resist Updat"},{"key":"72_CR38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/myc.12170","volume":"57","author":"MC Arendrup","year":"2014","unstructured":"Arendrup MC, Cuenca-Estrella M, Lass-Fl\u00f6rl C, Hope WW (2014) EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses 57:377\u2013379","journal-title":"Mycoses"},{"key":"72_CR39","volume-title":"Performance Standards for Antimicrobial Susceptebility Testing: Nineteenth Informational Supplement M100-S19","author":"Clinical and Laboratory Standards Insitute","year":"2009","unstructured":"Clinical and Laboratory Standards Insitute (2009) Performance Standards for Antimicrobial Susceptebility Testing: Nineteenth Informational Supplement M100-S19. CLSI, Wayne, PA"},{"key":"72_CR40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.drup.2010.09.002","volume":"13","author":"MA Pfaller","year":"2010","unstructured":"Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D (2010) Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 13:180\u2013195","journal-title":"Drug Resist Updat"},{"key":"72_CR41","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.00262-08","volume":"52","author":"G Garcia-Effron","year":"2008","unstructured":"Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS (2008) A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 52:2305\u20132312","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR42","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/JCM.44.5.1740-1743.2006","volume":"44","author":"AA Panackal","year":"2006","unstructured":"Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA (2006) Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 44:1740\u20131743","journal-title":"J Clin Microbiol"},{"key":"72_CR43","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1128\/JCM.32.9.2092-2098.1994","volume":"32","author":"M Ruhnke","year":"1994","unstructured":"Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M (1994) Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 32:2092\u20132098","journal-title":"J Clin Microbiol"},{"key":"72_CR44","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/01.tp.0000173771.47698.7b","volume":"80","author":"BD Alexander","year":"2005","unstructured":"Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR (2005) Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 80:868\u2013871","journal-title":"Transplantation"},{"key":"72_CR45","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1128\/EC.00151-07","volume":"6","author":"A Coste","year":"2007","unstructured":"Coste A, Selmecki A, Forche A, Diogo D, Bougnoux M-E, D\u2019Enfert C, Berman J, Sanglard D (2007) Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell 6:1889\u20131904","journal-title":"Eukaryot Cell"},{"key":"72_CR46","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/507895","volume":"43","author":"T Bicanic","year":"2006","unstructured":"Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G (2006) Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 43:1069\u20131073","journal-title":"Clin Infect Dis"},{"key":"72_CR47","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/jac\/dkm095","volume":"59","author":"M-T Baixench","year":"2007","unstructured":"Baixench M-T, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S, Ramires S, Piketty C, Dannaoui E (2007) Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 59:1076\u20131083","journal-title":"J Antimicrob Chemother"},{"key":"72_CR48","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1128\/AAC.00148-06","volume":"50","author":"M Hakki","year":"2006","unstructured":"Hakki M, Staab JF, Marr KA (2006) Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 50:2522\u20132524","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR49","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.49.2.767-769.2005","volume":"49","author":"V Moudgal","year":"2005","unstructured":"Moudgal V, Little T, Boikov D, Vazquez JA (2005) Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49:767\u2013769","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR50","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1128\/AAC.01568-07","volume":"52","author":"JD Cleary","year":"2008","unstructured":"Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS (2008) Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 52:2263\u20132265","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR51","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.01193-12","volume":"57","author":"RH Jensen","year":"2013","unstructured":"Jensen RH, Johansen HK, Arendrup MC (2013) Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob Agents Chemother 57:614\u2013617","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR52","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1128\/AAC.02037-12","volume":"57","author":"A Fekkar","year":"2013","unstructured":"Fekkar A, Meyer I, Brossas JY, Dannaoui E, Palous M, Uzunov M, Nguyen S, Leblond V, Mazier D, Datry A (2013) Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. Antimicrob Agents Chemother 57:2380\u20132382","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR53","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","volume":"56","author":"BD Alexander","year":"2013","unstructured":"Alexander BD, Johnson MD, Pfeiffer CD, Jim\u00e9nez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA (2013) Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724\u20131732","journal-title":"Clin Infect Dis"},{"key":"72_CR54","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1128\/AAC.00027-12","volume":"56","author":"RK Shields","year":"2012","unstructured":"Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ (2012) The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 56:4862\u20134869","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR55","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1128\/JCM.06112-11","volume":"50","author":"MA Pfaller","year":"2012","unstructured":"Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN (2012) Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 50:1199\u20131203","journal-title":"J Clin Microbiol"},{"key":"72_CR56","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1128\/AAC.01138-09","volume":"54","author":"F Chapeland-Leclerc","year":"2010","unstructured":"Chapeland-Leclerc F, Hennequin C, Papon N, No\u00ebl T, Girard A, Soci\u00e9 G, Ribaud P, Lacroix C (2010) Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 54:1360\u20131362","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR57","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/QCO.0000000000000111","volume":"27","author":"MC Arendrup","year":"2014","unstructured":"Arendrup MC, Perlin DS (2014) Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis 27:484\u2013492","journal-title":"Curr Opin Infect Dis"},{"key":"72_CR58","unstructured":"Jensen RH, Johansen HK, S\u00f8es LM, Lemming LE, Rosenvinge FS, Nielsen L, Olesen BRS, Kristensen L, Leitz C, Arendrup MC (2014) Abstract 0083: Post-treatment antifungal resistance among colonising Candida isolates in candidaemia patients: preliminary results from a systematic multi-centre study. Proc. 24th Eur. Congr. Clin. Microbiol. Infect. Dis. S 45. Copenhagen. https:\/\/www.escmid.org\/escmid_library\/online_lecture_library\/ . Zugegriffen: 11 Mai 2014"},{"key":"72_CR59","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrmicro1179","volume":"3","author":"JB Anderson","year":"2005","unstructured":"Anderson JB (2005) Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 3:547\u2013556","journal-title":"Nat Rev Microbiol"},{"key":"72_CR60","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF01967067","volume":"11","author":"M Pfaller","year":"1992","unstructured":"Pfaller M, Riley J (1992) Effects of fluconazole on the sterol and carbohydrate composition of four species of Candida. Eur J Clin Microbiol Infect Dis 11:152\u2013156","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"72_CR61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.fgb.2009.09.003","volume":"47","author":"LA Walker","year":"2010","unstructured":"Walker LA, Gow NAR, Munro CA (2010) Fungal echinocandin resistance. Fungal Genet Biol 47:117\u2013126","journal-title":"Fungal Genet Biol"},{"key":"72_CR62","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/AAC.00683-11","volume":"56","author":"KK Lee","year":"2012","unstructured":"Lee KK, Maccallum DM, Jacobsen MD, Walker LA, Odds FC, Gow NAR, Munro CA (2012) Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother 56:208\u2013217","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR63","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1128\/AAC.00136-13","volume":"57","author":"RK Shields","year":"2013","unstructured":"Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ (2013) Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 57:3528\u20133535","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR64","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B Pauw De","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) C. Clin Infect Dis 46:1813\u20131821","journal-title":"Clin Infect Dis"},{"key":"72_CR65","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/AAC.01128-10","volume":"55","author":"O Lortholary","year":"2011","unstructured":"Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F (2011) Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 55:532\u2013538","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR66","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1002\/cncr.24507","volume":"115","author":"NV Sipsas","year":"2009","unstructured":"Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston K V, Raad II, Kontoyiannis DP (2009) Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001\u20132007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115:4745\u20134752","journal-title":"Cancer"},{"issue":"3","key":"72_CR67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12465","volume":"20","author":"AM Tortorano","year":"2014","unstructured":"Tortorano AM, Richardson M, Roilides E et al (2014) ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect 20(Suppl 3):27\u201346","journal-title":"Clin Microbiol Infect"},{"key":"72_CR68","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","volume":"46","author":"TJ Walsh","year":"2008","unstructured":"Walsh TJ, Anaissie EJ, Denning DW et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327\u2013360","journal-title":"Clin Infect Dis"},{"issue":"3","key":"72_CR69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","volume":"20","author":"OA Cornely","year":"2014","unstructured":"Cornely OA, Arikan-Akdagli S, Dannaoui E et al (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 20(Suppl 3):5\u201326","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"72_CR70","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/1469-0691.12360","volume":"20","author":"MC Arendrup","year":"2014","unstructured":"Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect 20(Suppl 3):76\u201398","journal-title":"Clin Microbiol Infect"},{"key":"72_CR71","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1128\/JCM.37.7.2343-2345.1999","volume":"37","author":"DA Sutton","year":"1999","unstructured":"Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG (1999) In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 37:2343\u20132345","journal-title":"J Clin Microbiol"},{"key":"72_CR72","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/cncr.20554","volume":"101","author":"RY Hachem","year":"2004","unstructured":"Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP, Chatzinikolaou I, Perego C, Kantarjian HM, Raad II (2004) Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101:1594\u20131600","journal-title":"Cancer"},{"key":"72_CR73","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/EC.4.3.625-632.2005","volume":"4","author":"SA Balajee","year":"2005","unstructured":"Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA (2005) Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell 4:625\u2013632","journal-title":"Eukaryot Cell"},{"key":"72_CR74","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/48.6.919","volume":"48","author":"A G\u00f3mez-L\u00f3pez","year":"2001","unstructured":"G\u00f3mez-L\u00f3pez A, Cuenca-Estrella M, Monz\u00f3n A, Rodriguez-Tudela JL (2001) In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole. J Antimicrob Chemother 48:919\u2013921","journal-title":"J Antimicrob Chemother"},{"key":"72_CR75","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/43.1.149","volume":"43","author":"M Cuenca-Estrella","year":"1999","unstructured":"Cuenca-Estrella M, Ruiz-D\u00edez B, Mart\u00ednez-Su\u00e1rez J V, Monz\u00f3n A, Rodr\u00edguez-Tudela JL (1999) Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 43:149\u2013151","journal-title":"J Antimicrob Chemother"},{"key":"72_CR76","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2006.08.017","volume":"28","author":"SJ Howard","year":"2006","unstructured":"Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, Denning DW (2006) Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 28:450\u2013453","journal-title":"Int J Antimicrob Agents"},{"key":"72_CR77","doi-asserted-by":"crossref","first-page":"e1001692","DOI":"10.1371\/journal.pbio.1001692","volume":"11","author":"BM Vincent","year":"2013","unstructured":"Vincent BM, Lancaster AK, Scherz-Shouval R, Whitesell L, Lindquist S (2013) Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol 11:e1001692","journal-title":"PLoS Biol"},{"key":"72_CR78","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1111\/j.1439-0507.2011.02045.x","volume":"54","author":"OA Cornely","year":"2011","unstructured":"Cornely OA, Marty FM, Stucker F, Pappas PG, Ullmann AJ (2011) Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease. Mycoses 54:e838\u2013e847","journal-title":"Mycoses"},{"key":"72_CR79","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2334-11-261","volume":"11","author":"AC Reboli","year":"2011","unstructured":"Reboli AC, Shorr AF, Rotstein C, Pappas PG, Kett DH, Schlamm HT, Reisman AL, Biswas P, Walsh TJ (2011) Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis 11:261","journal-title":"BMC Infect Dis"},{"key":"72_CR80","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","volume":"46","author":"A Pascual","year":"2008","unstructured":"Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201\u2013211","journal-title":"Clin Infect Dis"},{"key":"72_CR81","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","volume":"34","author":"DW Denning","year":"2002","unstructured":"Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563\u2013571","journal-title":"Clin Infect Dis"},{"key":"72_CR82","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","volume":"36","author":"LB Johnson","year":"2003","unstructured":"Johnson LB, Kauffman CA (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630\u2013637","journal-title":"Clin Infect Dis"},{"key":"72_CR83","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","volume":"53","author":"D Andes","year":"2009","unstructured":"Andes D, Pascual A, Marchetti O (2009) Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 53:24\u201334","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR84","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FTD.0b013e318167d0e0","volume":"30","author":"J Smith","year":"2008","unstructured":"Smith J, Andes D (2008) Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 30:167\u2013172","journal-title":"Ther Drug Monit"},{"key":"72_CR85","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","volume":"55","author":"WB Park","year":"2012","unstructured":"Park WB, Kim N-H, Kim K-H et al (2012) The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 55:1080\u20131087","journal-title":"Clin Infect Dis"},{"key":"72_CR86","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jac\/dkm125","volume":"60","author":"TH Nguyen","year":"2007","unstructured":"Nguyen TH, Hoppe-Tichy T, Geiss HK, Rastall AC, Swoboda S, Schmidt J, Weigand MA (2007) Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 60:100\u2013106","journal-title":"J Antimicrob Chemother"},{"key":"72_CR87","first-page":"179","volume":"19","author":"K-F Bodmann","year":"2010","unstructured":"Bodmann K-F, Grabein B et al (2010) Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen Update 2010. Chemother J 19:179\u2013255","journal-title":"Chemother J"},{"key":"72_CR88","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/00007890-199457120-00027","volume":"57","author":"R Ma\u00f1ez","year":"1994","unstructured":"Ma\u00f1ez R, Martin M, Raman D, Silverman D, Jain A, Warty V, Gonzalez-Pinto I, Kusne S, Starzl TE (1994) Fluconazole therapy in transplant recipients receiving FK506. Transplantation 57:1521\u20131523","journal-title":"Transplantation"},{"key":"72_CR89","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1067\/mcp.2002.121911","volume":"71","author":"AJ Romero","year":"2002","unstructured":"Romero AJ, Le Pogamp P, Nilsson L-G, Wood N (2002) Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 71:226\u2013234","journal-title":"Clin Pharmacol Ther"},{"key":"72_CR90","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.46.9.3091-3093.2002","volume":"46","author":"R Venkataramanan","year":"2002","unstructured":"Venkataramanan R, Zang S, Gayowski T, Singh N (2002) Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 46:3091\u20133093","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR91","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.bmt.1704516","volume":"34","author":"C Sanz-Rodriguez","year":"2004","unstructured":"Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al (2004) Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 34:13\u201320","journal-title":"Bone Marrow Transplant"},{"key":"72_CR92","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1086\/375080","volume":"36","author":"SC Deresinski","year":"2003","unstructured":"Deresinski SC, Stevens DA (2003) Caspofungin. Clin Infect Dis 36:1445\u20131457","journal-title":"Clin Infect Dis"},{"key":"72_CR93","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1177\/0091270005279580","volume":"45","author":"MF Hebert","year":"2005","unstructured":"Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I (2005) Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 45:1145\u20131152","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"72_CR94","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1439-0507.2008.01523.x","volume":"51","author":"H-P Lipp","year":"2008","unstructured":"Lipp H-P (2008) Antifungal agents\u2013clinical pharmacokinetics and drug interactions. Mycoses 51(Suppl 1):7\u201318","journal-title":"Mycoses"},{"key":"72_CR95","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200241140-00002","volume":"41","author":"P Paepe De","year":"2002","unstructured":"De Paepe P, Belpaire FM, Buylaert WA (2002) Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 41:1135\u20131151","journal-title":"Clin Pharmacokinet"},{"key":"72_CR96","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1007\/s00134-003-1980-z","volume":"29","author":"K Yagasaki","year":"2003","unstructured":"Yagasaki K, Gando S, Matsuda N, Kameue T, Ishitani T, Hirano T, Iseki K (2003) Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med 29:1844\u20131848","journal-title":"Intensive Care Med"},{"key":"72_CR97","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/jac\/40.5.695","volume":"40","author":"M Valtonen","year":"1997","unstructured":"Valtonen M, Tiula E, Neuvonen PJ (1997) Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother 40:695\u2013700","journal-title":"J Antimicrob Chemother"},{"key":"72_CR98","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","volume":"27","author":"T Felton","year":"2014","unstructured":"Felton T, Troke PF, Hope WW (2014) Tissue penetration of antifungal agents. Clin Microbiol Rev 27:68\u201388","journal-title":"Clin Microbiol Rev"},{"key":"72_CR99","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1128\/AAC.01560-10","volume":"55","author":"B Moriyama","year":"2011","unstructured":"Moriyama B, Ditullio M, Wilson E et al (2011) Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema. Antimicrob Agents Chemother 55:2478\u20132480","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/jac\/dkm169","volume":"60","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Lasso M, Betts R et al (2007) Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 60:363\u2013369","journal-title":"J Antimicrob Chemother"},{"key":"72_CR101","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1469-0691.2012.03784.x","volume":"18","author":"M Ruhnke","year":"2012","unstructured":"Ruhnke M, Paiva JA, Meersseman W et al (2012) Anidulafungin for the treatment of candidaemia\/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect 18:680\u2013687","journal-title":"Clin Microbiol Infect"},{"key":"72_CR102","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.idc.2013.09.004","volume":"28","author":"CA Kauffman","year":"2014","unstructured":"Kauffman CA (2014) Diagnosis and management of fungal urinary tract infection. Infect Dis Clin North Am 28:61\u201374","journal-title":"Infect Dis Clin North Am"},{"key":"72_CR103","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00003246-199905000-00020","volume":"27","author":"MJ Richards","year":"1999","unstructured":"Richards MJ, Edwards JR, Culver DH, Gaynes RP (1999) Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 27:887\u2013892","journal-title":"Crit Care Med"},{"key":"72_CR104","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02378-12","volume":"57","author":"KF Mitchell","year":"2013","unstructured":"Mitchell KF, Taff HT, Cuevas MA, Reinicke EL, Sanchez H, Andes DR (2013) Role of matrix \u03b2-1,3 glucan in antifungal resistance of non-albicans Candida biofilms. Antimicrob Agents Chemother 57:1918\u20131920","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR105","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1128\/AAC.46.6.1773-1780.2002","volume":"46","author":"DM Kuhn","year":"2002","unstructured":"Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA (2002) Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46:1773\u20131780","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR106","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4155\/fmc.13.189","volume":"6","author":"N Delattin","year":"2014","unstructured":"Delattin N, Cammue BPA, Thevissen K (2014) Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms. Future Med Chem 6:77\u201390","journal-title":"Future Med Chem"},{"key":"72_CR107","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jac\/dkh071","volume":"53","author":"H Lamfon","year":"2004","unstructured":"Lamfon H, Porter SR, McCullough M, Pratten J (2004) Susceptibility of Candida albicans biofilms grown in a constant depth film fermentor to chlorhexidine, fluconazole and miconazole: a longitudinal study. J Antimicrob Chemother 53:383\u2013385","journal-title":"J Antimicrob Chemother"},{"key":"72_CR108","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1001\/archinte.1995.00430220087009","volume":"155","author":"MH Nguyen","year":"1995","unstructured":"Nguyen MH, Peacock JE, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, Wagener MM, Yu VL (1995) Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 155:2429\u20132435","journal-title":"Arch Intern Med"},{"key":"72_CR109","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/clinids\/21.4.994","volume":"21","author":"JH Rex","year":"1995","unstructured":"Rex JH, Bennett JE, Sugar AM, Pappas PG, Serody J, Edwards JE, Washburn RG (1995) Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 21:994\u2013996","journal-title":"Clin Infect Dis"},{"key":"72_CR110","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","volume":"54","author":"DR Andes","year":"2012","unstructured":"Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54:1110\u20131122","journal-title":"Clin Infect Dis"},{"key":"72_CR111","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/CCM.0000000000000221","volume":"42","author":"M Puig-Asensio","year":"2014","unstructured":"Puig-Asensio M, Pem\u00e1n J, Zaragoza R, Garnacho-Montero J, Mart\u00edn-Mazuelos E, Cuenca-Estrella M, Almirante B (2014) Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med 42:1423\u20131432","journal-title":"Crit Care Med"},{"key":"72_CR112","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","volume":"54","author":"DR Andes","year":"2012","unstructured":"Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54:1110\u20131122","journal-title":"Clin Infect Dis"},{"key":"72_CR113","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrmicro732","volume":"1","author":"A Casadevall","year":"2003","unstructured":"Casadevall A, Pirofski L (2003) The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 1:17\u201324","journal-title":"Nat Rev Microbiol"},{"key":"72_CR114","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00003246-199601000-00026","volume":"24","author":"RC Bone","year":"1996","unstructured":"Bone RC (1996) Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24:163\u2013172","journal-title":"Crit Care Med"},{"key":"72_CR115","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/CCM.0b013e3181cc4734","volume":"38","author":"Y Cohen","year":"2010","unstructured":"Cohen Y, Karoubi P, Adrie C, Gauzit R, Marsepoil T, Zarka D, Clec\u2019h C (2010) Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients. Crit Care Med 38:826\u2013830","journal-title":"Crit Care Med"},{"key":"72_CR116","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1473-3099(04)01045-X","volume":"4","author":"MASH Mennink-Kersten","year":"2004","unstructured":"Mennink-Kersten MASH, Donnelly JP, Verweij PE (2004) Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 4:349\u2013357","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"72_CR117","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1469-0691.2008.01980.x","volume":"14","author":"H Einsele","year":"2008","unstructured":"Einsele H, Loeffler J (2008) Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients. Clin Microbiol Infect 14(Suppl 4):37\u201345","journal-title":"Clin Microbiol Infect"},{"key":"72_CR118","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1007\/s00134-009-1482-8","volume":"35","author":"W Meersseman","year":"2009","unstructured":"Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, Van Wijngaerden E (2009) Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 35:1526\u20131531","journal-title":"Intensive Care Med"},{"key":"72_CR119","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/432470","volume":"41","author":"L Ostrosky-Zeichner","year":"2005","unstructured":"Ostrosky-Zeichner L, Alexander BD, Kett DH et al (2005) Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41:654\u2013659","journal-title":"Clin Infect Dis"},{"key":"72_CR120","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1128\/JCM.37.5.1510-1517.1999","volume":"37","author":"B Sendid","year":"1999","unstructured":"Sendid B, Tabouret M, Poirot JL, Mathieu D, Fruit J, Poulain D (1999) New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol 37:1510\u20131517","journal-title":"J Clin Microbiol"},{"key":"72_CR121","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2334-7-103","volume":"7","author":"FF Alam","year":"2007","unstructured":"Alam FF, Mustafa AS, Khan ZU (2007) Comparative evaluation of (1, 3)-beta-D-glucan, mannan and anti-mannan antibodies, and Candida species-specific snPCR in patients with candidemia. BMC Infect Dis 7:103","journal-title":"BMC Infect Dis"},{"key":"72_CR122","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.diagmicrobio.2004.08.015","volume":"51","author":"M Prella","year":"2005","unstructured":"Prella M, Bille J, Pugnale M, Duvoisin B, Cavassini M, Calandra T, Marchetti O (2005) Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 51:95\u2013101","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"7","key":"72_CR123","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1469-0691.12038","volume":"18","author":"M Cuenca-Estrella","year":"2012","unstructured":"Cuenca-Estrella M, Verweij PE, Arendrup MC et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 18(Suppl 7):9\u201318","journal-title":"Clin Microbiol Infect"},{"key":"72_CR124","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1086\/382224","volume":"38","author":"C Viscoli","year":"2004","unstructured":"Viscoli C, Machetti M, Cappellano P, Bucci B, Bruzzi P, Van Lint MT, Bacigalupo A (2004) False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 38:913\u2013916","journal-title":"Clin Infect Dis"},{"key":"72_CR125","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1128\/JCM.42.11.5362-5363.2004","volume":"42","author":"D Mattei","year":"2004","unstructured":"Mattei D, Rapezzi D, Mordini N, Cuda F, Lo Nigro C, Musso M, Arnelli A, Cagnassi S, Gallamini A (2004) False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol 42:5362\u20135363","journal-title":"J Clin Microbiol"},{"key":"72_CR126","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000046037","volume":"89","author":"A Kato","year":"2001","unstructured":"Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A (2001) Elevation of blood (1-->3)-beta-D-glucan concentrations in hemodialysis patients. Nephron 89:15\u201319","journal-title":"Nephron"},{"key":"72_CR127","first-page":"1413","volume":"44","author":"A Nakao","year":"1997","unstructured":"Nakao A, Yasui M, Kawagoe T, Tamura H, Tanaka S, Takagi H (1997) False-positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular carcinoma with cirrhosis. Hepatogastroenterology 44:1413\u20131418","journal-title":"Hepatogastroenterology"},{"key":"72_CR128","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00134-012-2616-y","volume":"38","author":"C Le\u00f3n","year":"2012","unstructured":"Le\u00f3n C, Ruiz-Santana S, Saavedra P et al (2012) Value of \u03b2-D-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions. Intensive Care Med 38:1315\u20131325","journal-title":"Intensive Care Med"},{"key":"72_CR129","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1473-3099(07)70085-3","volume":"7","author":"N Singh","year":"2007","unstructured":"Singh N, Perfect JR (2007) Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 7:395\u2013401","journal-title":"Lancet Infect Dis"},{"key":"72_CR130","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2165\/00003495-200565110-00007","volume":"65","author":"GM Keating","year":"2005","unstructured":"Keating GM (2005) Posaconazole. Drugs 65:1553\u20131567. (discussion 1568\u20131569)","journal-title":"Drugs"},{"key":"72_CR131","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/AAC.05134-11","volume":"55","author":"OA Cornely","year":"2011","unstructured":"Cornely OA, Vehreschild JJ, Vehreschild MJGT et al (2011) Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother 55:5798\u20135803","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR132","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1128\/AAC.48.9.3407-3411.2004","volume":"48","author":"DA Stevens","year":"2004","unstructured":"Stevens DA, Espiritu M, Parmar R (2004) Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48:3407\u20133411","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR133","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1128\/AAC.00946-13","volume":"58","author":"C Rueda","year":"2014","unstructured":"Rueda C, Cuenca-Estrella M, Zaragoza O (2014) Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence. Antimicrob Agents Chemother 58:1071\u20131083","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR134","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/AAC.50.4.1293-1297.2006","volume":"50","author":"KV Clemons","year":"2006","unstructured":"Clemons KV, Espiritu M, Parmar R, Stevens DA (2006) Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 50:1293\u20131297","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jcpt.12046","volume":"38","author":"M Fink","year":"2013","unstructured":"Fink M, Zerlauth U, Kaulfersch C, Rab A, Alberer D, Preiss P, Sternad-Klobschauer K, Habernig E, Wandschneider W, Grimm G (2013) A severe case of haemodynamic instability during anidulafungin administration. J Clin Pharm Ther 38:241\u2013242","journal-title":"J Clin Pharm Ther"},{"key":"72_CR136","doi-asserted-by":"crossref","unstructured":"Lichtenstern C, Wolff M, Arens C, Klie F, Majeed RW, Henrich M, Uhle F, Weiterer S, R\u00f6hrig R, Weigand MA (2013) Cardiac effects of echinocandin preparations \u2013 three case reports. J Clin Pharm Ther. doi:10.1111\/jcpt.12078","DOI":"10.1111\/jcpt.12078"},{"key":"72_CR137","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00101-014-2289-8","volume":"63","author":"C Arens","year":"2014","unstructured":"Arens C, Uhle F, Wolff M et al (2014) Effects of echinocandin preparations on adult rat ventricular cardiomyocytes. Preliminary results of an in vitro study. Anaesthesist 63:129\u2013134","journal-title":"Anaesthesist"},{"key":"72_CR138","doi-asserted-by":"crossref","unstructured":"Koch C, Uhle F, Wolff M et al (2014) Cardiac effects of echinocandins after central venous administration in adult rats. Antimicrob Agents Chemother. doi:10.1128\/AAC.04446-14","DOI":"10.1128\/AAC.04446-14"},{"key":"72_CR139","doi-asserted-by":"crossref","unstructured":"Stover KR, Farley JM, Kyle PB, Cleary JD (2013) Cardiac toxicity of some echinocandin antifungals. Expert Opin Drug Saf. doi:10.1517\/14740338.2013.829036","DOI":"10.1517\/14740338.2013.829036"},{"key":"72_CR140","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1053\/jinf.1999.0605","volume":"40","author":"K Darling","year":"2000","unstructured":"Darling K, Singh J, Wilks D (2000) Successful treatment of Candida glabrata endophthalmitis with amphotericin B lipid complex (ABLC). J Infect 40:92\u201394","journal-title":"J Infect"},{"key":"72_CR141","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/clinids\/6.6.791","volume":"6","author":"RA Smego","year":"1984","unstructured":"Smego RA, Perfect JR, Durack DT (1984) Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 6:791\u2013801","journal-title":"Rev Infect Dis"},{"key":"72_CR142","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/apc.1998.12.681","volume":"12","author":"JL Casado","year":"1998","unstructured":"Casado JL, Quereda C, Corral I (1998) Candidal meningitis in HIV-infected patients. AIDS Patient Care STDS 12:681\u2013686","journal-title":"AIDS Patient Care STDS"},{"key":"72_CR143","first-page":"227","volume":"50","author":"L Houmeau","year":"1993","unstructured":"Houmeau L, Monfort-Gouraud M, Boccara JF, Badoual J (1993) [Candida meningitis, in a premature infant, treated with liposomal amphotericin B and flucytosine]. Arch fran\u00e7aises p\u00e9diatrie 50:227\u2013230","journal-title":"Arch fran\u00e7aises p\u00e9diatrie"},{"key":"72_CR144","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","volume":"39","author":"KA Marr","year":"2004","unstructured":"Marr KA, Boeckh M, Carter RA, Kim HW, Corey L (2004) Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39:797\u2013802","journal-title":"Clin Infect Dis"},{"key":"72_CR145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/423389","volume":"39","author":"C Viscoli","year":"2004","unstructured":"Viscoli C (2004) Combination therapy for invasive aspergillosis. Clin Infect Dis 39:803\u2013805","journal-title":"Clin Infect Dis"},{"key":"72_CR146","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1086\/428674","volume":"40","author":"S Cesaro","year":"2005","unstructured":"Cesaro S, Visintin G (2005) Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 40:1073\u20131075. (author reply 1075\u20131076)","journal-title":"Clin Infect Dis"},{"key":"72_CR147","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10096-002-0877-z","volume":"22","author":"BP Howden","year":"2003","unstructured":"Howden BP, Slavin MA, Schwarer AP, Mijch AM (2003) Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 22:111\u2013113","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"72_CR148","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1439-0507.2003.00878.x","volume":"46","author":"IB Gosbell","year":"2003","unstructured":"Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC (2003) Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 46:233\u2013336","journal-title":"Mycoses"},{"key":"72_CR149","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/00365540600786564","volume":"39","author":"S V Bhat","year":"2007","unstructured":"Bhat S V, Paterson DL, Rinaldi MG, Veldkamp PJ (2007) Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis 39:87\u201390","journal-title":"Scand J Infect Dis"},{"key":"72_CR150","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1086\/598933","volume":"48","author":"RF Betts","year":"2009","unstructured":"Betts RF, Nucci M, Talwar D et al (2009) A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 48:1676\u20131684","journal-title":"Clin Infect Dis"},{"key":"72_CR151","doi-asserted-by":"crossref","first-page":"R159","DOI":"10.1186\/cc8117","volume":"13","author":"BF Dupont","year":"2009","unstructured":"Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V (2009) Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care 13:R159","journal-title":"Crit Care"},{"key":"72_CR152","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","volume":"36","author":"JR Perfect","year":"2003","unstructured":"Perfect JR, Marr KA, Walsh TJ et al (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36:1122\u20131131","journal-title":"Clin Infect Dis"},{"key":"72_CR153","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-003-1014-3","volume":"22","author":"L Ostrosky-Zeichner","year":"2003","unstructured":"Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, Rex JH (2003) Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22:651\u2013665","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"72_CR154","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0002-9343(96)80072-6","volume":"101","author":"EJ Anaissie","year":"1996","unstructured":"Anaissie EJ, Vartivarian SE, Abi-Said D, et al (1996) Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 101:170\u2013176","journal-title":"Am J Med"},{"key":"72_CR155","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/313583","volume":"30","author":"CA Kauffman","year":"2000","unstructured":"Kauffman CA, Vazquez JA, Sobel JD et al (2000) Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 30:14\u201318","journal-title":"Clin Infect Dis"},{"key":"72_CR156","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10096-010-1061-5","volume":"30","author":"SG Revankar","year":"2011","unstructured":"Revankar SG, Hasan MS, Revankar VS, Sobel JD (2011) Long-term follow-up of patients with candiduria. Eur J Clin Microbiol Infect Dis 30:137\u2013140","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"72_CR157","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1086\/313580","volume":"30","author":"JD Sobel","year":"2000","unstructured":"Sobel JD, Kauffman CA, McKinsey D, Zervos M, Vazquez JA, Karchmer AW, Lee J, Thomas C, Panzer H, Dismukes WE (2000) Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 30:19\u201324","journal-title":"Clin Infect Dis"},{"key":"72_CR158","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1517\/13543784.13.8.903","volume":"13","author":"RR Arthur","year":"2004","unstructured":"Arthur RR, Drew RH, Perfect JR (2004) Novel modes of antifungal drug administration. Expert Opin Investig Drugs 13:903\u2013932","journal-title":"Expert Opin Investig Drugs"},{"key":"72_CR159","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1086\/510432","volume":"44","author":"JD Sobel","year":"2007","unstructured":"Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA (2007) Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 44:e46\u2013e49","journal-title":"Clin Infect Dis"},{"key":"72_CR160","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000077331","volume":"36","author":"D Goldblum","year":"2004","unstructured":"Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S (2004) Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model. Ophthalmic Res 36:172\u2013176","journal-title":"Ophthalmic Res"},{"key":"72_CR161","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1128\/AAC.46.12.3719-3723.2002","volume":"46","author":"D Goldblum","year":"2002","unstructured":"Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S (2002) Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 46:3719\u20133723","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR162","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0002-9394(14)71234-6","volume":"119","author":"JK Luttrull","year":"1995","unstructured":"Luttrull JK, Wan WL, Kubak BM, Smith MD, Oster HA (1995) Treatment of ocular fungal infections with oral fluconazole. Am J Ophthalmol 119:477\u2013481","journal-title":"Am J Ophthalmol"},{"key":"72_CR163","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0002-9394(14)71537-5","volume":"113","author":"L Laatikainen","year":"1992","unstructured":"Laatikainen L, Tuominen M, von Dickhoff K (1992) Treatment of endogenous fungal endophthalmitis with systemic fluconazole with or without vitrectomy. Am J Ophthalmol 113:205\u2013207","journal-title":"Am J Ophthalmol"},{"key":"72_CR164","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/clinids\/20.3.657","volume":"20","author":"ME Akler","year":"1995","unstructured":"Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL (1995) Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 20:657\u2013664","journal-title":"Clin Infect Dis"},{"key":"72_CR165","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/cid\/cir355","volume":"53","author":"AML Oude Lashof","year":"2011","unstructured":"Oude Lashof AML, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, Oborska IT, Rex JH, Kullberg BJ (2011) Ocular manifestations of candidemia. Clin Infect Dis 53:262\u2013268","journal-title":"Clin Infect Dis"},{"key":"72_CR166","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00762-06","volume":"51","author":"MA Thiel","year":"2007","unstructured":"Thiel MA, Zinkernagel AS, Burhenne J, Kaufmann C, Haefeli WE (2007) Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 51:239\u2013244","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR167","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajo.2004.08.077","volume":"139","author":"SM Breit","year":"2005","unstructured":"Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG (2005) Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 139:135\u2013140","journal-title":"Am J Ophthalmol"},{"key":"72_CR168","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3928\/1542-8877-19970301-03","volume":"28","author":"TF Essman","year":"1997","unstructured":"Essman TF, Flynn HW, Smiddy WE, Brod RD, Murray TG, Davis JL, Rubsamen PE (1997) Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 28:185\u2013194","journal-title":"Ophthalmic Surg Lasers"},{"key":"72_CR169","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/IAE.0b013e31822d3a34","volume":"32","author":"A Sallam","year":"2012","unstructured":"Sallam A, Taylor SRJ, Khan A, McCluskey P, Lynn WA, Manku K, Pacheco PA, Lightman S (2012) Factors determining visual outcome in endogenous Candida endophthalmitis. Retina 32:1129\u20131134","journal-title":"Retina"},{"key":"72_CR170","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/00365549509032745","volume":"27","author":"JO Jarl\u00f8v","year":"1995","unstructured":"Jarl\u00f8v JO, Born P, Bruun B (1995) Candida albicans meningitis in a 27 weeks premature infant treated with liposomal amphotericin-B (AmBisome). Scand J Infect Dis 27:419\u2013420","journal-title":"Scand J Infect Dis"},{"key":"72_CR171","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood-2005-02-0733","volume":"106","author":"S Schwartz","year":"2005","unstructured":"Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Lutsar I, Troke P, Thiel E (2005) Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106:2641\u20132645","journal-title":"Blood"},{"key":"72_CR172","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1128\/AAC.00949-10","volume":"55","author":"S Weiler","year":"2011","unstructured":"Weiler S, Fiegl D, MacFarland R, Stienecke E, Bellmann-Weiler R, Dunzendorfer S, Joannidis M, Bellmann R (2011) Human tissue distribution of voriconazole. Antimicrob Agents Chemother 55:925\u2013928","journal-title":"Antimicrob Agents Chemother"},{"key":"72_CR173","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0163-4453(00)80017-1","volume":"40","author":"MJ Aleixo","year":"2000","unstructured":"Aleixo MJ, Caldeira L, Ferreira ML (2000) Candida albicans meningitis: clinical case. J Infect 40:191\u2013192","journal-title":"J Infect"},{"key":"72_CR174","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1086\/317550","volume":"32","author":"ME Ellis","year":"2001","unstructured":"Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W (2001) Fungal endocarditis: evidence in the world literature, 1965\u20131995. Clin Infect Dis 32:50\u201362","journal-title":"Clin Infect Dis"},{"key":"72_CR175","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MD.0b013e3181a693f8","volume":"88","author":"M Falcone","year":"2009","unstructured":"Falcone M, Barzaghi N, Carosi G et al (2009) Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) 88:160\u2013168","journal-title":"Medicine (Baltimore)"},{"key":"72_CR176","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1439-0507.2010.01884.x","volume":"54","author":"JM Boland","year":"2011","unstructured":"Boland JM, Chung HH, Robberts FJL, Wilson WR, Steckelberg JM, Baddour LM, Miller DV (2011) Fungal prosthetic valve endocarditis: Mayo Clinic experience with a clinicopathological analysis. Mycoses 54:354\u2013360","journal-title":"Mycoses"},{"key":"72_CR177","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.1111\/j.1469-0691.2012.03764.x","volume":"18","author":"A Lefort","year":"2012","unstructured":"Lefort A, Chartier L, Sendid B, Wolff M, Mainardi J-L, Podglajen I, Desnos-Ollivier M, Fontanet A, Bretagne S, Lortholary O (2012) Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect 18:E99\u2013E109","journal-title":"Clin Microbiol Infect"},{"key":"72_CR178","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/clinids\/23.1.176","volume":"23","author":"C Hennequin","year":"1996","unstructured":"Hennequin C, Bour\u00e9e P, Hiesse C, Dupont B, Charpentier B (1996) Spondylodiskitis due to Candida albicans: report of two patients who were successfully treated with fluconazole and review of the literature. Clin Infect Dis 23:176\u2013178","journal-title":"Clin Infect Dis"},{"key":"72_CR179","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1086\/322634","volume":"33","author":"DJ Miller","year":"2001","unstructured":"Miller DJ, Mejicano GC (2001) Vertebral osteomyelitis due to Candida species: case report and literature review. Clin Infect Dis 33:523\u2013530","journal-title":"Clin Infect Dis"},{"key":"72_CR180","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3109\/03009749509100883","volume":"24","author":"BL Hansen","year":"1995","unstructured":"Hansen BL, Andersen K (1995) Fungal arthritis. A review. Scand J Rheumatol 24:248\u2013250","journal-title":"Scand J Rheumatol"},{"key":"72_CR181","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13693780701552996","volume":"46","author":"A Schilling","year":"2008","unstructured":"Schilling A, Seibold M, Mansmann V, Gleissner B (2008) Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin\/posaconazole therapy. Med Mycol 46:79\u201383","journal-title":"Med Mycol"},{"key":"72_CR182","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0049-0172(98)80003-6","volume":"27","author":"A P\u00e9rez-G\u00f3mez","year":"1998","unstructured":"P\u00e9rez-G\u00f3mez A, Prieto A, Torresano M, D\u00edez E, Mulero J, Labiano I, Andreu JL (1998) Role of the new azoles in the treatment of fungal osteoarticular infections. Semin Arthritis Rheum 27:226\u2013244","journal-title":"Semin Arthritis Rheum"},{"key":"72_CR183","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1086\/521253","volume":"45","author":"U Sili","year":"2007","unstructured":"Sili U, Yilmaz M, Ferhanoglu B, Mert A (2007) Candida krusei arthritis in a patient with hematologic malignancy: successful treatment with voriconazole. Clin Infect Dis 45:897\u2013898","journal-title":"Clin Infect Dis"},{"key":"72_CR184","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/00365540500447192","volume":"38","author":"L Legout","year":"2006","unstructured":"Legout L, Assal M, Rohner P, Lew D, Bernard L, Hoffmeyer P (2006) Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient. Scand J Infect Dis 38:728\u2013730","journal-title":"Scand J Infect Dis"},{"key":"72_CR185","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/00365540903253510","volume":"42","author":"T Kelesidis","year":"2010","unstructured":"Kelesidis T, Tsiodras S (2010) Candida albicans prosthetic hip infection in elderly patients: is fluconazole monotherapy an option? Scand J Infect Dis 42:12\u201321","journal-title":"Scand J Infect Dis"}],"container-title":["Der Anaesthesist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-015-0072-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00101-015-0072-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-015-0072-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:20:50Z","timestamp":1718065250000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00101-015-0072-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":185,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["72"],"URL":"https:\/\/doi.org\/10.1007\/s00101-015-0072-0","relation":{},"ISSN":["0003-2417","1432-055X"],"issn-type":[{"value":"0003-2417","type":"print"},{"value":"1432-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}